AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
AIM ImmunoTech(AIM) Newsfilter·2024-01-22 21:55临床试验 - AIM ImmunoTech Inc.宣布在Erasmus Medical Center招募了第一位受试者，进行了与AstraZeneca的Imfinzi®联合治疗晚期胰腺癌的临床试验[1] - DURIPANC研究的主要目标是确定Imfinzi和Ampligen联合治疗的安全性和临床益处率[2] 治疗潜力 - Ampligen作为联合治疗的潜力在于增加免疫细胞的数量和活性，从而提高对抗癌症的效果，该疗法有望成为治疗胰腺癌的突破[4]